Optimizing use of GLP-1 receptor agonists: safety, tolerability, adherence, and patient selection in cardiovascular practice

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have fundamentally transformed modern cardiometabolic care, moving beyond glycemic control to become a cornerstone of obesity management and potent cardiovascular risk reduction. Large-scale clinical trials consistently highlight their cardioprotective benefits, demonstrating significant reductions in major adverse cardiovascular events (MACE), cardiovascular mortality, and obesity-related heart failure complications. However, translating these remarkable clinical trial successes into routine clinical practice reveals a marked gap between efficacy and effectiveness, primarily driven by suboptimal patient persistence and adherence. This narrative review synthesizes current evidence regarding the pharmacology, safety, tolerability, adherence, and patient selection of GLP-1RAs to support optimal therapeutic decision-making in cardiovascular practice. While long-term data disprove clear causal relationships with pancreatic or thyroid malignancies, a high incidence of predictable, dose-related gastrointestinal adverse events (nausea, vomiting, diarrhea) remains the leading cause of early treatment discontinuation. Additionally, treatment persistence in clinical practice is heavily influenced by financial burdens, supply chain instability, and formulation choices. Cardioprotective benefits are well-established for patients with type 2 diabetes and atherosclerotic cardiovascular disease. Mitigating challenges in clinical practice requires a systematic, multi-step prescribing framework focused on targeted patient selection, gradual individualized dose titration ("start low and go slow"), and proactive multidisciplinary symptom management.

Authors

Institutions

Publication Details

Journal
Journal of Cardiovascular Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.1097/fjc.0000000000001901
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Optimizing use of GLP-1 receptor agonists: safety, tolerability, adherence, and patient selection in cardiovascular practice

Ana V. Pejčić, Miloš N. Milosavljević, Srđjan Stefanović
3 links
Journal of Cardiovascular Pharmacology
Diabetes Treatment and Management
article

Optimizing use of GLP-1 receptor agonists: safety, tolerability, adherence, and patient selection in cardiovascular practice

Ana V. Pejčić, Miloš N. Milosavljević, Srđjan Stefanović
article en

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have fundamentally transformed modern cardiometabolic care, moving beyond glycemic control to become a cornerstone of obesity management and potent cardiovascular risk reduction. Large-scale clinical trials consistently highlight their cardioprotective benefits, demonstrating significant reductions in major adverse cardiovascular events (MACE), cardiovascular mortality, and obesity-related heart failure complications. However, translating these remarkable clinical trial successes into routine clinical practice reveals a marked gap between efficacy and effectiveness, primarily driven by suboptimal patient persistence and adherence. This narrative review synthesizes current evidence regarding the pharmacology, safety, tolerability, adherence, and patient selection of GLP-1RAs to support optimal therapeutic decision-making in cardiovascular practice. While long-term data disprove clear causal relationships with pancreatic or thyroid malignancies, a high incidence of predictable, dose-related gastrointestinal adverse events (nausea, vomiting, diarrhea) remains the leading cause of early treatment discontinuation. Additionally, treatment persistence in clinical practice is heavily influenced by financial burdens, supply chain instability, and formulation choices. Cardioprotective benefits are well-established for patients with type 2 diabetes and atherosclerotic cardiovascular disease. Mitigating challenges in clinical practice requires a systematic, multi-step prescribing framework focused on targeted patient selection, gradual individualized dose titration ("start low and go slow"), and proactive multidisciplinary symptom management.

Journal of Cardiovascular Pharmacology
University of Kragujevac (RS), Clinical Centre of Kragujevac (RS)
Good health and well-being
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon